OXBOF (Oxford BioDynamics) LT-Debt-to-Total-Asset : 0.39 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Oxford BioDynamics's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.39.

Oxford BioDynamics's long-term debt to total assets ratio increased from Sep. 2023 (0.35) to Sep. 2024 (0.39). It may suggest that Oxford BioDynamics is progressively becoming more dependent on debt to grow their business.

Oxford BioDynamics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Oxford BioDynamics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics LT-Debt-to-Total-Asset Chart

Oxford BioDynamics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.39

0.48

0.35

0.39

Oxford BioDynamics Semi-Annual Data
	Sep14	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.48	0.35	0.35	0.47	0.39

Oxford BioDynamics LT-Debt-to-Total-Asset Calculation

Oxford BioDynamics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )	/	Total Assets (A: Sep. 2024 )
	=	6.209	/	16.016
	=	0.39

Oxford BioDynamics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	6.209	/	16.016
	=	0.39

Oxford BioDynamics (OTCPK:OXBOF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Oxford BioDynamics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioDynamics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

OBD:UK LMQ:Germany

Address

John Smith Drive, 3140 Rowan Place, ARC Oxford, Oxford, GBR, OX4 2WB

Website

https://www.oxfordbiodynamics.com

Oxford BioDynamics PLC is a biotechnology company engaged in developing and commercializing precision clinical diagnostic tests for life-changing diseases. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The tests are based on the company's proprietary 3D genomic biomarker platform, EpiSwitch which enables screening, evaluation, validation, and monitoring of biomarkers. In addition, the company offers, EpiSwitch Explorer Array Kit for 3D genome profiling. It is also developing new tests in the areas of oncology, neurology, inflammation, hepatology, and animal health. Geographically, it derives key revenue from the United States of America.